DUETACT

LOE Approaching

pioglitazone and glimepiride

NDAORALTABLET
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
57

Mechanism of Action

2 antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class, and glimepiride, a member of the sulfonylurea class. Thiazolidinediones are insulin-sensitizing agents that act…

Pharmacologic Class:

Sulfonylurea

Clinical Trials (5)

NCT03501277Phase 1Completed

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Started May 2018
72 enrolled
Healthy Volunteers
NCT02823808Phase 4Unknown

Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function

Started Jul 2017
96 enrolled
Diabetes
NCT02989649N/ATerminated

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Started Dec 2016
593 enrolled
Diabetes Mellitus, Type 2
NCT02763007Phase 4Terminated

An Extension Study of PEAK Trial

Started May 2016
41 enrolled
Diabetes Mellitus, Type 2
NCT01990300N/ACompleted

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Started Nov 2011
3,281 enrolled
Type 2 Diabetes Mellitus

Loss of Exclusivity

LOE Date
Jun 8, 2028
27 months away
Patent Expiry
Jun 8, 2028

Patent Records (2)

Patent #ExpiryTypeUse Code
7700128
Jan 30, 2027
Product
8071130
Jun 8, 2028
Product